Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FCM for Anemia in Cancer Patients on Chemotherapy
NCT04246021Completed
- Sponsor
- King Hussein Cancer Center
- Start
- Jun 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of ferric carboxymaltose in anemia, sponsored by King Hussein Cancer Center. Primary endpoints: Median Hemoglobin Change From Baseline at 12 weeks, Percentage of Patients With Hb Increment of at Least 1.0 g/dL at 12 weeks and 1 more. Started Jun 2016; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
anemia
Beyond the preview
Go deeper on NCT04246021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04246021.